EP4103742A4 - PROXIMITY DOSING - Google Patents

PROXIMITY DOSING Download PDF

Info

Publication number
EP4103742A4
EP4103742A4 EP21753829.7A EP21753829A EP4103742A4 EP 4103742 A4 EP4103742 A4 EP 4103742A4 EP 21753829 A EP21753829 A EP 21753829A EP 4103742 A4 EP4103742 A4 EP 4103742A4
Authority
EP
European Patent Office
Prior art keywords
proximity assay
assay
proximity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21753829.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4103742A1 (en
Inventor
Jia Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Absci Corp
Original Assignee
Absci Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/013734 external-priority patent/WO2021146626A1/en
Application filed by Absci Corp filed Critical Absci Corp
Publication of EP4103742A1 publication Critical patent/EP4103742A1/en
Publication of EP4103742A4 publication Critical patent/EP4103742A4/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Valve Device For Special Equipments (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP21753829.7A 2020-02-11 2021-02-11 PROXIMITY DOSING Pending EP4103742A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975152P 2020-02-11 2020-02-11
PCT/US2021/013734 WO2021146626A1 (en) 2020-01-15 2021-01-15 Activity-specific cell enrichment
PCT/US2021/017688 WO2021163349A1 (en) 2020-02-11 2021-02-11 Proximity assay

Publications (2)

Publication Number Publication Date
EP4103742A1 EP4103742A1 (en) 2022-12-21
EP4103742A4 true EP4103742A4 (en) 2024-06-05

Family

ID=77292601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21753829.7A Pending EP4103742A4 (en) 2020-02-11 2021-02-11 PROXIMITY DOSING

Country Status (8)

Country Link
EP (1) EP4103742A4 (zh)
JP (1) JP2023513578A (zh)
CN (1) CN115362263A (zh)
AU (1) AU2021218706A1 (zh)
CA (1) CA3170531A1 (zh)
IL (1) IL295335A (zh)
MX (1) MX2022009783A (zh)
WO (1) WO2021163349A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122567A1 (en) 2021-12-21 2023-06-29 Absci Corporation Fola selection assay to identify strains with increased soluble target protein expression
WO2023122448A1 (en) 2021-12-23 2023-06-29 Absci Corporation Products and methods for heterologous expression of proteins in a host cell
WO2023129881A1 (en) 2021-12-30 2023-07-06 Absci Corporation Knockout of ptsp gene elevates active gene expression
US20230268026A1 (en) 2022-01-07 2023-08-24 Absci Corporation Designing biomolecule sequence variants with pre-specified attributes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003067210A2 (en) * 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
US20080261829A1 (en) * 2006-09-21 2008-10-23 Prometheus Laboratories Inc. Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
WO2016000966A1 (en) * 2014-06-30 2016-01-07 Nestec S.A. Collaborative enzyme enhanced reactive (ceer) immunoassay using flow cytometry

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687615A1 (en) * 2003-11-19 2006-08-09 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003067210A2 (en) * 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
US20080261829A1 (en) * 2006-09-21 2008-10-23 Prometheus Laboratories Inc. Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
WO2016000966A1 (en) * 2014-06-30 2016-01-07 Nestec S.A. Collaborative enzyme enhanced reactive (ceer) immunoassay using flow cytometry

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Taking protein phosphorylation measurement one step further", vol. 11807_02, 31 July 2014 (2014-07-31), pages 1 - 8, XP009510111, Retrieved from the Internet <URL:https://www.perkinelmer.com/lab-solutions/resources/docs/BRO_AlphaLISA_SureFire_Ultra.pdf> *
DONG YUAN ET AL: "Generation of a Monoclonal Antibody against D-Dimer Using HTS-Based LiCA", SLAS DISCOVERY: ADVANCING LIFE SCIENCES R&D, MARY ANN LIEBERT, vol. 25, no. 3, 27 September 2019 (2019-09-27), XP009526706, ISSN: 2472-5552, [retrieved on 20200229], DOI: 10.1177/2472555219878407 *
EGLEN RICHARD M ET AL: "The use of AlphaScreen technology in HTS: current status", CURRENT CHEMICAL GENOMICS, BENTHAM OPEN, NL, vol. 1, 1 January 2008 (2008-01-01), pages 2 - 10, XP008176468, ISSN: 1875-3973, [retrieved on 20080225], DOI: 10.2174/1875397300801010002 *
HAOLIN LIU: "A Rapid Method to Characterize Mouse IgG Antibodies and Isolate Native Antigen Binding IgG B Cell Hybridomas", PLOS ONE, vol. 10, no. 8, 28 August 2015 (2015-08-28), US, pages e0136613, XP093153510, ISSN: 1932-6203, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552657/pdf/pone.0136613.pdf> DOI: 10.1371/journal.pone.0136613 *
JAE HEE LEE: "Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment", BIODRUGS, vol. 33, no. 4, 12 June 2019 (2019-06-12), NZ, pages 411 - 422, XP093153395, ISSN: 1173-8804, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s40259-019-00362-5.pdf> DOI: 10.1007/s40259-019-00362-5 *
MIYAKAWA SHUUICHI ET AL: "Development of novel highly sensitive methods to detect endogenous cGAMP in cells and tissue", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 480, 23 January 2020 (2020-01-23), XP086150152, ISSN: 0022-1759, [retrieved on 20200123], DOI: 10.1016/J.JIM.2020.112751 *
MUNEOKA SATOSHI ET AL: "Development of a novel immunoassay to select antibodies against intact membrane antigens by using the homogeneous AlphaLISA system", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM, NL, vol. 126, no. 4, 29 May 2018 (2018-05-29), pages 522 - 526, XP085491491, ISSN: 1389-1723, DOI: 10.1016/J.JBIOSC.2018.04.018 *
NGUYEN ANNALEE W ET AL: "Identification of high affinity HER2 binding antibodies using CHO Fab surface display", PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 31, no. 3, 1 March 2018 (2018-03-01), GB, pages 91 - 101, XP093149973, ISSN: 1741-0126, DOI: 10.1093/protein/gzy004 *
See also references of WO2021163349A1 *
SEREBRYANNYY LEONID A ET AL: "HiPLA: High-throughput imaging proximity ligation assay", METHODS, vol. 157, 10 November 2018 (2018-11-10), pages 80 - 87, XP085615567, ISSN: 1046-2023, DOI: 10.1016/J.YMETH.2018.11.004 *
WADHWA MEENU ET AL: "Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 43, no. 5, 3 July 2015 (2015-07-03), pages 298 - 306, XP029269961, ISSN: 1045-1056, DOI: 10.1016/J.BIOLOGICALS.2015.06.004 *
YUKAKO SENGA: "AlphaScreen-based homogeneous assay using a pair of 25-residue artificial proteins for high-throughput analysis of non-native IgG", SCIENTIFIC REPORTS, vol. 7, no. 1, 29 September 2017 (2017-09-29), US, XP093152676, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-017-12693-w.pdf> DOI: 10.1038/s41598-017-12693-w *

Also Published As

Publication number Publication date
WO2021163349A1 (en) 2021-08-19
IL295335A (en) 2022-10-01
EP4103742A1 (en) 2022-12-21
CN115362263A (zh) 2022-11-18
MX2022009783A (es) 2022-11-09
CA3170531A1 (en) 2021-08-19
JP2023513578A (ja) 2023-03-31
AU2021218706A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
EP4103742A4 (en) PROXIMITY DOSING
EP4129176A4 (en) BIOSENSOR
GB202011617D0 (en) Assay
EP4129179A4 (en) BIOSENSOR
IL307174A (en) examination
EP4085254C0 (en) ADA REACTION SPECIFICATION ASSAY
EP4129662A4 (en) BIOSENSOR
EP4129178A4 (en) BIOSENSOR
EP4060017A4 (en) TEST CHIP
AU2021900166A0 (en) Assay
AU2020904671A0 (en) Assay
AU2022900310A0 (en) Assay
GB202119033D0 (en) Assay
GB202117513D0 (en) Assay
GB202115077D0 (en) Assay
GB202115072D0 (en) Assay
GB202112296D0 (en) Assay
GB202109886D0 (en) Assay
GB202108853D0 (en) Assay
GB202105117D0 (en) Assay
GB202015211D0 (en) Assay
GB202015122D0 (en) Assay
GB202014570D0 (en) Complementome assay
GB202307576D0 (en) C3a1-hne assay
GB202301141D0 (en) Pro-c5 assay

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220909

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230513

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12Q0001682000

Ipc: G01N0033577000

A4 Supplementary search report drawn up and despatched

Effective date: 20240507

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/542 20060101ALI20240430BHEP

Ipc: G01N 33/58 20060101ALI20240430BHEP

Ipc: G01N 33/577 20060101AFI20240430BHEP